用于阿尔茨海默病的临床抗糖尿病药物：从基础发现到治疗药物开发。
Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development.
作者信息
Huang Juan, Huang Nanqu, Cui Di, Shi Jingshan, Qiu Yu
机构信息
Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China.
出版信息
Front Aging Neurosci. 2023 Feb 10;15:1122300. doi: 10.3389/fnagi.2023.1122300. eCollection 2023.
Abstract
Alzheimer's disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.
摘要
阿尔茨海默病（AD）是一种常见的神经退行性疾病。2型糖尿病（T2DM）似乎会增加患AD的风险并促使其发病。因此，人们越来越关注用于AD治疗的临床抗糖尿病药物。它们中的大多数在基础研究中显示出一定潜力，但在临床研究中却并非如此。所以我们回顾了一些用于AD治疗的抗糖尿病药物从基础研究到临床研究所面临的机遇与挑战。基于现有的研究进展，这对于一些由血糖升高和/或胰岛素抵抗引起的特殊类型AD患者来说仍抱有希望。
相似文献
1
Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development.
Front Aging Neurosci. 2023 Feb 10;15:1122300. doi: 10.3389/fnagi.2023.1122300. eCollection 2023.
2
Global View on Alzheimer's Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer's Disease and Diabetes Mellitus.
Curr Alzheimer Res. 2018;15(14):1277-1282. doi: 10.2174/1567205015666180925110222.
3
Natural bioactive compounds in Alzheimer's disease: From the perspective of type 3 diabetes mellitus.
Front Aging Neurosci. 2023 Mar 16;15:1130253. doi: 10.3389/fnagi.2023.1130253. eCollection 2023.
4
Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Int Rev Neurobiol. 2020;155:37-64. doi: 10.1016/bs.irn.2020.02.010. Epub 2020 Aug 11.
5
A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.
J Alzheimers Dis. 2022;85(2):485-501. doi: 10.3233/JAD-210612.
6
Alzheimer's disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities.
Neurol Neurochir Pol. 2021;55(5):418-428. doi: 10.5603/PJNNS.a2021.0056. Epub 2021 Aug 6.
7
Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents.
Curr Med Chem. 2020;27(39):6658-6681. doi: 10.2174/0929867326666191011144818.
8
Alzheimer's disease and type 2 diabetes mellitus: A systematic review of proteomic studies.
J Neurochem. 2021 Mar;156(6):753-776. doi: 10.1111/jnc.15166. Epub 2020 Oct 7.
9
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Br J Clin Pharmacol. 2011 Mar;71(3):365-76. doi: 10.1111/j.1365-2125.2010.03830.x.
10
Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer's Disease.
touchREV Endocrinol. 2023 May;19(1):16-24. doi: 10.17925/EE.2023.19.1.16. Epub 2023 May 23.
引用本文的文献
1
The multifaceted roles of apolipoprotein E4 in Alzheimer's disease pathology and potential therapeutic strategies.
Cell Death Discov. 2025 Jul 8;11(1):312. doi: 10.1038/s41420-025-02600-y.
2
Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.
J Prev Alzheimers Dis. 2025 May;12(5):100111. doi: 10.1016/j.tjpad.2025.100111. Epub 2025 Feb 28.
3
The role of AMPKα subunit in Alzheimer's disease: In-depth analysis and future prospects.
Heliyon. 2024 Jul 6;10(13):e34254. doi: 10.1016/j.heliyon.2024.e34254. eCollection 2024 Jul 15.
4
Novel targets and therapies of metformin in dementia: old drug, new insights.
Front Pharmacol. 2024 May 31;15:1415740. doi: 10.3389/fphar.2024.1415740. eCollection 2024.
5
Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review.
Cureus. 2023 Sep 6;15(9):e44763. doi: 10.7759/cureus.44763. eCollection 2023 Sep.
本文引用的文献
1
Lecanemab for Alzheimer's disease: tempering hype and hope.
Lancet. 2022 Dec 3;400(10367):1899. doi: 10.1016/S0140-6736(22)02480-1.
2
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study.
Diabetologia. 2022 Oct;65(10):1664-1675. doi: 10.1007/s00125-022-05743-0. Epub 2022 Jul 29.
3
Association Between Metformin and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Clinical Observational Studies.
J Alzheimers Dis. 2022;88(4):1311-1323. doi: 10.3233/JAD-220180.
4
Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study.
Geroscience. 2022 Jun;44(3):1791-1805. doi: 10.1007/s11357-022-00568-6. Epub 2022 Apr 20.
5
Association Between Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Cognitive Function in a Longitudinal Study of Patients with Type 2 Diabetes.
J Alzheimers Dis. 2022;87(2):635-642. doi: 10.3233/JAD-215678.
6
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
Diabetes Care. 2022 May 1;45(5):1247-1251. doi: 10.2337/dc21-2434.
7
Low-dose metformin targets the lysosomal AMPK pathway through PEN2.
Nature. 2022 Mar;603(7899):159-165. doi: 10.1038/s41586-022-04431-8. Epub 2022 Feb 23.
8
New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs.
Expert Opin Investig Drugs. 2022 Jan;31(1):105-123. doi: 10.1080/13543784.2022.2022122. Epub 2022 Jan 2.
9
Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study.
Sci Rep. 2021 Dec 15;11(1):24069. doi: 10.1038/s41598-021-03406-5.
10
Altered Hippocampal Subfields Volumes Is Associated With Memory Function in Type 2 Diabetes Mellitus.
Front Neurol. 2021 Nov 25;12:756500. doi: 10.3389/fneur.2021.756500. eCollection 2021.
Zotero 插件